(NASDAQ: BVS) Bioventus's forecast annual revenue growth rate of 8.75% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 12.21%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 1,548.07%.
Bioventus's revenue in 2026 is $563,829,000.On average, 4 Wall Street analysts forecast BVS's revenue for 2026 to be $50,747,092,296, with the lowest BVS revenue forecast at $48,688,771,164, and the highest BVS revenue forecast at $53,431,930,958.
In 2027, BVS is forecast to generate $54,020,377,410 in revenue, with the lowest revenue forecast at $51,722,870,589 and the highest revenue forecast at $56,663,006,833.